Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
- Resource Type
- Authors
- Satoshi Fujii; Koji Kuronuma; Yuta Ibe; Hiromasa Nakata; Hirotoshi Inamura; Yusuke Kunimoto; Yoshihiro Fujiya; Satoshi Takahashi; Masahide Fukudo; Tomoyuki Ishigo
- Source
- Journal of Infection and Chemotherapy
- Subject
- 0301 basic medicine
Microbiology (medical)
Male
medicine.medical_specialty
Multivariate analysis
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
030106 microbiology
Defervescence
Favipiravir
Antiviral Agents
03 medical and health sciences
0302 clinical medicine
Internal medicine
Early treatment
Medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Retrospective Studies
Receiver operating characteristic
business.industry
Proportional hazards model
SARS-CoV-2
Area under the curve
COVID-19
Retrospective cohort study
Amides
Infectious Diseases
Treatment Outcome
Pyrazines
Original Article
business
- Language
- English
- ISSN
- 1437-7780
1341-321X
INTRODUCTION: The antiviral drug favipiravir has been shown to have in vitro antiviral activity against severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2). In this study, we investigated the clinical benefits and initiation of favipiravir treatment in patients with non-severe coronavirus-disease-2019 (COVID-19). METHODS: This study was a single-center retrospective cohort study. Receiver operating characteristic curves were drawn to calculate the area under the curve, and the optimal cut-off values for the time to initiate favipiravir treatment were calculated to predict defervescence within seven days. Univariate and multivariate Cox regression analyses were performed to identify potential influencing factors of defervescence. This was defined as a body temperature of less than 37 °C for at least 2 days. RESULTS: Data from 41 patients were used for the efficacy assessment. The days from the onset of fever to defervescence showed a positive correlation with the duration from the onset of fever to initiation of favipiravir treatment (r = 0.548, P